TREX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Not a good buy right now for an impatient buyer. TREX is sitting just above near-term support (41.0) with weakening momentum (bearish MACD expansion) and no Intellectia buy signals. While fundamentals and several recent analyst upgrades are constructive, the tape is still soft and downside to the next support zone (39.9–41.0) is plausible before a cleaner entry appears.
Price/momentum: TREX is drifting lower (regular -0.86%, post -1.01%) and trading below the pivot (42.745), which is a near-term bearish setup. Indicators: MACD histogram is negative (-0.222) and expanding lower, signaling strengthening downside momentum. RSI(6) at ~41 is neutral-to-weak (not oversold), leaving room for further downside. Levels: Immediate support S1 ~40.997 (current area) then S2 ~39.917. Resistance begins at pivot 42.745, then R1 44.492. A convincing move back above 42.7 would improve the near-term trend; until then, risk/reward is not attractive for a buy-now decision.
support a recovery narrative.
Trend/momentum: Bearish MACD expansion and price below pivot indicate sellers still control the near term.
Institutional flow: Hedge Funds are selling (selling amount up ~236.05% over the last quarter), a material headwind.
Mixed Street view and housing sensitivity: Prior major target cuts/downgrades highlight macro/housing-rate risk; Barclays remains Underweight (PT $32).
Event risk: Next earnings 2026-02-24 (after hours). The calendar shows an EPS estimate of about -0.01 (seasonally weak quarter risk), which can keep pressure on the stock into the print.
News: No fresh positive catalyst in the last week to change momentum.
Latest quarter (2025/Q3): Revenue $285.35M (+22.09% YoY), Net Income $51.77M (+27.66% YoY), EPS $0.48 (+29.73% YoY), Gross Margin 40.94% (+2.66% YoY). Overall: strong growth and improving profitability in the most recent reported quarter.
Recent trend: Ratings/targets were cut sharply in Nov 2025 (e.g., Stifel downgrade; JPM/PT cuts; Barclays continued Underweight), but sentiment improved into Dec 2025–Jan 2026 with multiple upgrades (Jefferies Buy $42; UBS Buy $52; Wolfe Outperform $47) even as some targets were reduced earlier (Goldman still Buy but cut PT). Wall Street pros: Belief in margin floor/margin expansion potential, discounted valuation vs history, and eventual return to higher sales growth. Wall Street cons: Housing/repair-remodel softness, competitive/share-loss concerns, and near-term uncertainty that can keep the multiple and price pressured. Influential/political trading: No recent congress trading data available; no politician activity provided.
Intellectia Proprietary Trading Signals:
